Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,790 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib.
Lee SE, Choi SY, Bang JH, Kim SH, Jang EJ, Byeun JY, Park JE, Jeon HR, Oh YJ, Kim HJ, Kim YK, Park JS, Jeong SH, Kim SH, Zang DY, Oh S, Koo DH, Kim H, Do YR, Kwak JY, Kim JA, Kim DY, Mun YC, Mauro MJ, Kim DW. Lee SE, et al. Among authors: kim h, kim hj, kim yk, kim dw, kim sh, kim dy, kim ja. Am J Hematol. 2013 Jun;88(6):449-54. doi: 10.1002/ajh.23427. Epub 2013 Mar 28. Am J Hematol. 2013. PMID: 23440689 Free article.
Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients.
Park JS, Lee SE, Jeong SH, Jang EJ, Choi MY, Kim HJ, Kim YK, Kim SH, Zang DY, Oh S, Koo DH, Kim H, Do YR, Kwak JY, Kim JA, Kim DY, Mun YC, Lee WS, Chang MH, Park J, Kwon JH, Kim DW. Park JS, et al. Among authors: kim h, kim hj, kim yk, kim dw, kim sh, kim dy, kim ja. Leuk Lymphoma. 2016 Feb;57(2):341-347. doi: 10.3109/10428194.2015.1049166. Epub 2015 Jun 12. Leuk Lymphoma. 2016. PMID: 25947037
Comparison of Frequency and Sensitivity of BCR-ABL1 Kinase Domain Mutations in Asian and White Patients With Imatinib-resistant Chronic-Phase Chronic Myeloid Leukemia.
Kim H, Kim S, Kim HJ, Kim YK, Kwak JY, Yhim HY, Kim SH, Do YR, Oh S, Lee SE, Jootar S, Cui JW, Kim DW. Kim H, et al. Among authors: kim hj, kim yk, kim dw, kim sh, kim s. Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):e391-e399. doi: 10.1016/j.clml.2018.06.031. Epub 2018 Jul 4. Clin Lymphoma Myeloma Leuk. 2018. PMID: 30082224 Free article.
Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.
Kim SH, Menon H, Jootar S, Saikia T, Kwak JY, Sohn SK, Park JS, Jeong SH, Kim HJ, Kim YK, Oh SJ, Kim H, Zang DY, Chung JS, Shin HJ, Do YR, Kim JA, Kim DY, Choi CW, Park S, Park HL, Lee GY, Cho DJ, Shin JS, Kim DW. Kim SH, et al. Among authors: kim h, kim hj, kim yk, kim dw, kim dy, kim ja. Haematologica. 2014 Jul;99(7):1191-6. doi: 10.3324/haematol.2013.096776. Epub 2014 Apr 4. Haematologica. 2014. PMID: 24705186 Free PMC article. Clinical Trial.
Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS, Kim JY, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Minden MD, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD. Ahn JS, et al. Among authors: kim jy, kim dd, kim hj, kim yk, kim sh, kim ny. Ann Hematol. 2016 Jan;95(2):301-10. doi: 10.1007/s00277-015-2540-7. Epub 2015 Nov 4. Ann Hematol. 2016. PMID: 26537612
A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea.
Shin J, Koh Y, Yoon SH, Cho JY, Kim DY, Lee KH, Kim HJ, Ahn JS, Kim YK, Park J, Sohn SK, Moon JH, Lee YJ, Yoon S, Lee JO, Cheong JW, Kim KH, Kim SH, Kim HG, Kim H, Nam SH, Do YR, Park SG, Park SK, Bae SH, Song HH, Shin DY, Oh D, Kim MK, Jung CW, Park S, Kim I. Shin J, et al. Among authors: kim hg, kim h, kim hj, kim yk, kim dy, kim sh, kim i, kim kh, kim mk. Cancer Med. 2018 May;7(5):1814-1823. doi: 10.1002/cam4.1450. Epub 2018 Mar 25. Cancer Med. 2018. PMID: 29577674 Free PMC article. Clinical Trial.
Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.
Sohn SK, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW, Kim DH, Yoon SS, Kim H, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Kim H, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Moon JH, Park SY. Sohn SK, et al. Among authors: kim cs, kim bs, kim h, kim hj, kim yk, kim dh, kim mk. Leuk Lymphoma. 2011 Jun;52(6):1024-9. doi: 10.3109/10428194.2011.563885. Epub 2011 Apr 4. Leuk Lymphoma. 2011. PMID: 21463107 Clinical Trial.
A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia.
Huh J, Kim HJ, Jung CW, Kim HJ, Kim SH, Kim YK, Kim HJ, Shin MG, Moon JH, Sohn SK, Kim SH, Lee WS, Won JH, Mun YC, Kim H, Park J, Min WS, Kim DH; AML/MDS working party, Korean Society of Hematology. Huh J, et al. Among authors: kim h, kim hj, kim yk, kim dh, kim sh. Am J Hematol. 2012 Oct;87(10):961-8. doi: 10.1002/ajh.23281. Epub 2012 Aug 7. Am J Hematol. 2012. PMID: 22886749 Free article.
5,790 results